EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

A Self-Developed IL-6Rα Nanobody Alleviates Experimental Autoimmune Uveitis by Inhibiting Th1 and Th17 Cells

Bochen Yao, Dali Tong, Jiaojiao Qian, Yuewei Peng, Zhouhuan Xi, Niannian Fan, Feiyu Jin, Can Deng, Bofeng Li, Kai Dong

Inflammation · 2026

DOI: 10.1007/s10753-026-02540-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Inflammation, 2026. Verfasst von Bochen Yao und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of C…. Hauptthemen laut MEDLINE: Th17 Cells, Th1 Cells, Uveitis, Autoimmune Diseases. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Hefei Comprehensive National Science Center Institute of Health and Medicine Project, grants from the National Natural Science Foundation of China, USTC Research Funds of the Double First-Class Initiative.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Interleukin-6, a pleiotropic cytokine, initiates downstream signaling by binding to interleukin-6 receptor α (IL-6Rα) and glycoprotein 130 (GP130). Autoimmune uveitis, the most prevalent form of non-infectious uveitis, represents a serious sight-threatening ocular disorder. While corticosteroids remain the mainstay of treatment in clinical practice, their therapeutic utility is constrained by significant adverse effects. Emerging evidence highlights the pivotal role of IL-6 in autoimmune uveitis pathogenesis, particularly in promoting CD4+T cells differentiation into Type 17 helper T cells (Th17). In this study, we evaluated the therapeutic efficacy of a novel anti-IL-6Rα nanobody in experimental autoimmune uveitis (EAU) models. Peripheral blood mononuclear cells (PBMCs) from Vogt-Koyanagi-Harada (VKH) patients were used to further assess the translational relevance of the anti-IL-6Rα nanobody. Our results demonstrate that this nanobody not only suppressed Type 17 helper T cells but also Type 1 helper T cells (Th1). Furthermore, treatment with anti-IL-6Rα nanobody significantly reduced inflammatory mediators and ameliorated disease severity in murine models. In vitro studies using PBMCs from VKH patients revealed that the anti-IL-6Rα nanobody effectively suppressed both interferon-γ (IFN-γ) and IL-17 production. These findings collectively suggest that anti-IL-6Rα nanobody represents a promising therapeutic strategy for autoimmune uveitis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Th17 CellsTh1 CellsUveitisAutoimmune DiseasesSingle-Domain AntibodiesReceptors, Interleukin-6Interleukin-6 Receptor alpha SubunitAnimalsHumansMiceFemaleDisease Models, Animal

Stichwörter der Autor:innen

Anti-IL-6Rα nanobodyAutoimmune uveitisTh1 cellsTh17 cellsVKH

Substanzen

Single-Domain AntibodiesReceptors, Interleukin-6Interleukin-6 Receptor alpha Subunit

Autor:innen und Institutionen

  • Department of Ophthalmology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230001, P.R. China.
  • Department of Medical Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230001, China.
  • Bengbu Medical University, Bengbu, Anhui, China.
  • Department of Medical Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230001, China. libf@ustc.edu.cn.
  • Department of Ophthalmology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230001, P.R. China. dongkai777@ustc.edu.cn.
  • Department of Ophthalmology, Centre for Leading Medicine and Advanced Technologies of IHM, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, He…

Förderung

  • Hefei Comprehensive National Science Center Institute of Health and Medicine Project
  • grants from the National Natural Science Foundation of China
  • USTC Research Funds of the Double First-Class Initiative
  • Research Funds of Centre for Leading Medicine and Advanced Technologies of IHM
  • Scientific Research Project Funding of Anhui Provincial Education Department
  • Joint Fund for Medical Artificial Intelligence
  • Clinical and Translational Research Project of Anhui Province
  • Health Research Program of Anhui

Zitieren

APA

Yao, B., Tong, D., Qian, J., Peng, Y., Xi, Z., Fan, N., Jin, F., Deng, C., Li, B., & Dong, K. (2026). A Self-Developed IL-6Rα Nanobody Alleviates Experimental Autoimmune Uveitis by Inhibiting Th1 and Th17 Cells. Inflammation. https://doi.org/10.1007/s10753-026-02540-4

Vancouver

Yao B, Tong D, Qian J, Peng Y, Xi Z, Fan N, et al. A Self-Developed IL-6Rα Nanobody Alleviates Experimental Autoimmune Uveitis by Inhibiting Th1 and Th17 Cells. Inflammation. 2026. doi:10.1007/s10753-026-02540-4

BibTeX
@article{Yao2026,
  author = {Yao, Bochen and Tong, Dali and Qian, Jiaojiao and Peng, Yuewei and Xi, Zhouhuan and Fan, Niannian and Jin, Feiyu and Deng, Can and Li, Bofeng and Dong, Kai},
  title = {A Self-Developed IL-6Rα Nanobody Alleviates Experimental Autoimmune Uveitis by Inhibiting Th1 and Th17 Cells},
  journal = {Inflammation},
  year = {2026},
  doi = {10.1007/s10753-026-02540-4}
}
Kostenlos starten →